Inventor

Edward Nudelman

Inventor

Seattle, WA, US

Overview

1989–2015

Patent span

Human necessities

Primary field (CPC A)

Patents· 18 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

A61Kprimary

A61KPreparations for medical, dental or toiletry purposes36%

C07KPeptides15%

G01NInvestigating or analysing materials by determining their chemical or physical properties15%

C07HSugars13%

Y02ATechnologies for adaptation to climate change8%

Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests8%

A61PSpecific therapeutic activity of chemical compounds or medicinal preparations3%

C12PFermentation or enzyme-using processes to synthesise a desired chemical compound or composition or to separate optical isomers from a racemic mixture3%

PatentTitleYear

9,140,692'Methods of identifying glycopeptides recognized by disease-associated auto-antibodies'2015 6,432,681'Compositions for treating Escherichia coli urinary tract infections'2002 6,331,254'Methods of separation and detection'2001 6,130,205'Method for determining susceptibility to Escherichia coli urinary tract infections, method for diagnosing secretors and nonsecretors, and method and medicament for preventing Escherichia coli urinary tract infections'2000 5,955,624'Growth stimulating factors'1999 5,827,830'Plasmalopsychosines and plasmalocerebrosides'1998 5,798,386'Angiogenic lipid formulations'1998 5,756,453'Use of angiogenic lipids for vascularizing tissue'1998 5,710,175'Growth stimulating factors'1998 5,693,620'Plasmalopsychosines and plasmalocerebrosides'1997 5,421,733'Synthesis of Le.sup.x ; dimeric Le.sup.x (difucosyl Y.sub.2 ; III.sup.3 FucV.sup.3 FucnLc.sub.6 Cer); sialylated forms thereof; and analogues thereof'1995 5,418,129'Blood treatment method'1995 5,374,532'Method for determining susceptibility to escherichia coli urinary tract infections and method for diagnosing secretors and nonsecretors'1994 5,240,833'Method for the production of monoclonal antibodies directed to tumor-associated gangliosides and fucogangliosides'1993 5,227,160'Monoclonal antibody NUH2 capable of inactivating motility of human sperm, antigen defined by said monoclonal antibody and methods of using said monoclonal antibody and antigen'1993 5,030,723'Long-chain glycolipid structure'1991 5,011,920'Disialofucoganglioside immunogen and fucoganglioside monosialosyl Le.sup.a II'1991 4,851,511'Monoclonal antibody that specifically binds to disialosyl Le.sup.a'1989

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1989–1991Patents assigned to HUTCHINSON FRED CANCER RES (2)· patent assignee history

1989–2002Based in Seattle, WA, US· patent location history

1991–2002Patents assigned to BIOMEMBRANE INST (8)· patent assignee history

1998–2001Patents assigned to CELL THERAPEUTICS INC (5)· patent assignee history

1998Patents assigned to BIOMEMBRANE INTSTITUTE (1)· patent assignee history

2000–2002Patents assigned to UNIV WASHINGTON (2)· patent assignee history

2015Based in Beverly, MA, US· patent location history

Inventor activity

Assignee and location history derived from the patent record.

Assignees

Assignee	Patents	Span
BIOMEMBRANE INST	8	1991–2002
CELL THERAPEUTICS INC	5	1998–2001
HUTCHINSON FRED CANCER RES	2	1989–1991
UNIV WASHINGTON	2	2000–2002
BIOMEMBRANE INTSTITUTE	1	1998

Locations

Location	Patents	Span
Seattle, Washington, US	17	1989–2002
Beverly, Massachusetts, US	1	2015